Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yimu Fuyan Granules is a Traditional Chinese Medicine (TCM) developed and manufactured by Jianmin Pharmaceutical Group. It is primarily indicated for the treatment of gynecological conditions, specifically chronic pelvic inflammatory disease (PID) and chronic pelvic pain. The formulation is composed of several herbal ingredients, including *Leonurus japonicus* (Motherwort), *Salvia miltiorrhiza* (Danshen), *Paeonia lactiflora* (Red Peony Root), *Cyperus rotundus*, and *Corydalis yanhusuo*. According to TCM principles, the drug works by promoting blood circulation, resolving blood stasis, clearing heat, and alleviating pain. Pharmacologically, it has been shown to exert anti-inflammatory and analgesic effects, likely through the modulation of inflammatory cytokines and improvement of local microcirculation in the pelvic cavity. It is widely used in China as a standard treatment for patients presenting with symptoms of damp-heat stasis, such as lower abdominal pain and lumbosacral soreness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yimu Fuyan Granules.